M S Hecker|M G Lebwohl - JoVE Visualize

Showing results (11-20 of 35) with videos related to

Pageof 4

Sort By:

Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2022

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasisJ J Wu, A Kavanaugh, M G Lebwohl, et al.

Archives of Dermatology|February 1, 1991

Eosinophilic fasciitis associated with tryptophan ingestion. A manifestation of eosinophilia-myalgia syndromeM L Gordon, M G Lebwohl, R G Phelps, et al.

Journal of the American Geriatrics Society|April 1, 1996

Apparent idiopathic hyponatremia in an ambulatory geriatric populationM Miller, M S Hecker, D A Friedlander, et al.

Journal of the American Academy of Dermatology|May 1, 1996

Infectious complications of erythrodermic psoriasisM S Green, J H Prystowsky, S R Cohen, et al.

The British Journal of Dermatology|July 6, 2019

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trialsS Hsu, L J Green, M G Lebwohl, et al.

Cutis|July 1, 1997

Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasisJ L Jorizzo, K Magee, D M Stewart, et al.

Archives of Pathology & Laboratory Medicine|December 1, 1993

Multiple hamartoma syndrome with osteosarcomaB C Yen, H Kahn, A L Schiller, et al.

Journal of the American Academy of Dermatology|August 14, 1998

Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks--apparent regression with hemodialysisA N Sapadin, M G Lebwohl, S A Teich, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2020

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trialR B Warren, J M Carrascosa, E Fumero, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2021

Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label studyM G Lebwohl, L Stein Gold, K Papp, et al.

Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:

Pageof 4

Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2022

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasisJ J Wu, A Kavanaugh, M G Lebwohl, et al.

Archives of Dermatology|February 1, 1991

Eosinophilic fasciitis associated with tryptophan ingestion. A manifestation of eosinophilia-myalgia syndromeM L Gordon, M G Lebwohl, R G Phelps, et al.

Journal of the American Geriatrics Society|April 1, 1996

Apparent idiopathic hyponatremia in an ambulatory geriatric populationM Miller, M S Hecker, D A Friedlander, et al.

Journal of the American Academy of Dermatology|May 1, 1996

Infectious complications of erythrodermic psoriasisM S Green, J H Prystowsky, S R Cohen, et al.

The British Journal of Dermatology|July 6, 2019

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trialsS Hsu, L J Green, M G Lebwohl, et al.

Cutis|July 1, 1997

Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasisJ L Jorizzo, K Magee, D M Stewart, et al.

Archives of Pathology & Laboratory Medicine|December 1, 1993

Multiple hamartoma syndrome with osteosarcomaB C Yen, H Kahn, A L Schiller, et al.

Journal of the American Academy of Dermatology|August 14, 1998

Periumbilical pseudoxanthoma elasticum associated with chronic renal failure and angioid streaks--apparent regression with hemodialysisA N Sapadin, M G Lebwohl, S A Teich, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2020

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trialR B Warren, J M Carrascosa, E Fumero, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2021

Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label studyM G Lebwohl, L Stein Gold, K Papp, et al.

Pageof 4